KYNTRA BIO, INC. Total Long-Term Debt
KYNTRA BIO, INC. (KYNB) had Total Long-Term Debt of $75.00 million as of 2025-08-29, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LongTermDebt · last filed 2026-08-13
- 2025-08-29: Long-term Debt $75.00M.
| Period end | Long-term Debt |
|---|---|
| 2025-08-29 | $75.00M 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |